Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin

Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin (Regulatory Post Marketing Commitment Plan)

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

All the patients whom an investigator prescribes the first Exemestane (Aromasin) should be registered.

Inclusion Criteria:

• Subjects with postmenopausal breast cancer (including ovariectomy etc.).

Exclusion Criteria:

• Patients cannot be evaluated.For example, not administered Exemestane (Aromasin).